In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Outcomes-Based Funding Deals On The Up In EU But Are They The Right Tool?

Outcomes-based reimbursement agreement are becoming increasingly popular in Europe. They’re complicated, there’s no “one size fits all” and it’s important companies and payers alike know what’s involved, says a forthcoming report.

Europe Government Payers

Scottish HTA Okays Neuroblastoma Ultra Orphan Qarziba

The Scottish Medicines Consortium has recommended EUSA’s ultra-orphan neuroblastoma treatment Qarziba.

Health Technology Assessment Government Payers

Mexico and Argentina To Cut Burden for Pharma By Swapping GMP Reports

Medicines regulators in Mexico and Argentina have agreed to exchange good manufacturing practices inspection certificates.

South America Argentina

The Strategic Advantages of Early Access Programs

Providing access to unlicensed medicines can offer companies big strategic advantages.

Market Access Regulation

The Advantages Of Providing Access To Unlicensed Medicines

Providing access to novel medicines through early access programs or supplying markets where medicines remain unlicensed has key benefits for the innovative drug development industry; revealing market insights and strategic opportunities.

Market Access Pricing Strategies

What Might Brazil’s Divisive New President Bring Pharma?

The Pink Sheet looks at the impact Brazil’s divisive new president elect might have on healthcare and the pharmaceutical industry. Top-level reorganization or depleted healthcare budgets?

South America Brazil
See All
Advertisement
UsernamePublicRestriction

Register